Form4insider filings, from the source

SEC Form 4 · accession 0000919574-18-004819

Avalo Therapeutics, Inc. · AVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
ARMISTICE CAPITAL, LLC
Director · 10% Owner
Steven Boyd
Director · 10% Owner
Period of report
Jul 16, 2018
Accepted (ET)
Jul 18, 2018 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Jul 16, 2018P13,800$4.2572A16,432,000D
Common StockF2Jul 16, 2018P$00$0.00A16,432,000ISee Footnote
Common StockF2Jul 16, 2018P$00$0.00A16,432,000ISee Footnote
Common StockF1Jul 16, 2018P4,000$4.254A16,436,000D
Common StockF2Jul 16, 2018P$00$0.00A16,436,000ISee Footnote
Common StockF2Jul 16, 2018P$00$0.00A16,436,000ISee Footnote
Common StockF1Jul 17, 2018P9,719$4.2982A16,445,719D
Common StockF2Jul 17, 2018P$00$0.00A16,445,719ISee Footnote
Common StockF2Jul 17, 2018P$00$0.00A16,445,719ISee Footnote
Common StockF1Jul 18, 2018P2,500$4.3462A16,448,219D
Common StockF2Jul 18, 2018P$00$0.00A16,448,219ISee Footnote
Common StockF2Jul 18, 2018P$00$0.00A16,448,219ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
WARRANTSF1,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714D
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I
WARRANTSF2,F3$0.40holding————Jun 30, 2022COMMON STOCK14,285,71414,285,714I

Explanation of responses